Adj. EBITDA of USD 44m above with ARCe and cons at USD 32 / USD 30m
EBITDA’22 is expected to exceed guidance of USD 115-140m
Expect marketed utilisation to reach 98% based on near-term awards
Solid report, we expect the shares to move higher today
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Adj. EBITDA of USD 44m above with ARCe and cons at USD 32 / USD 30m
EBITDA’22 is expected to exceed guidance of USD 115-140m
Expect marketed utilisation to reach 98% based on near-term awards
Solid report, we expect the shares to move higher today
